Could a single pill tackle both blood pressure and cholesterol?
NCT ID NCT07784621
First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time
Summary
This early-stage trial is asking whether two medications—one for blood pressure and one for cholesterol—can be safely taken together without affecting how each works. Healthy adult volunteers will receive each drug alone and then both together, so researchers can compare drug levels in the body. The goal is to see if combining them into one treatment is a viable option for people with both conditions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Losartan (HUC2A-752-A) and a combination of pitavastatin and ezetimibe (HUC2A-752-B)
- What this could lead to
- If the drugs don't interact, it could support combining them into a single pill for people with both high blood pressure and high cholesterol.
- What could go wrong
- This is an early, small study in healthy volunteers, so results may not reflect real patients. There is also a chance the drugs do interact, which would require dose adjustments.
Why investors are watching
Huons is running a phase 1 trial in 30 healthy adults to see if two of its experimental drugs, HUC2A-752-A and HUC2A-752-B, interact when taken together. For a small company, this readout matters because it will show whether the drugs can be combined safely and predictably, which is a basic checkpoint before any later-stage testing.
If it works: If the trial shows no harmful interaction and the drugs behave as expected, Huons can move the combination forward with more confidence. That progress could strengthen the company's pipeline and its position with partners or investors.
If it fails: Phase 1 trials often fail or reveal problems, and a bad interaction or safety issue could delay or stop the program. A setback here would hurt Huons because the company has few other public catalysts to lean on.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy adult volunteers * Individuals with a body weight between 50.0 kg and 90.0 kg and a BMI between 18.5 kg/m² and 29.9 kg/m² Exclusion Criteria: * Individuals with a history or presence of clinically significant diseases of the following systems: hepatobiliary, renal, neurological, immunological, respiratory, gastrointestinal, endocrine, hematologic/oncologic, cardiovascular , musculoskeletal, urological, psychiatric, or sexual dysfunction. * Individuals with a history of gastrointestinal diseases or gastrointestinal surgeries that could affect the safety or pharmacokinetic evaluation of the investigational product. * Individuals with a history of hypersensitivity or clinically significant hypersensitivity reactions to losartan, pitavastatin, ezetimibe, angiotensin receptor blockers, statins, or any other medications.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypertension are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, Jongno-gu, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized coaching via smartphone could curb hypertension before it starts
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Can stress explain the link between obesity and high blood pressure?
- Can a herbal formula match traditional medicine for brain bleeds?
- Could a helping hand with housing and food cut hospital visits?
- Brain scans and peer support: a new test for beating high blood pressure in african american women